The AI in oncology market size was valued at USD 4.22 billion in 2024 and is expected to reach USD 27.17 billion by 2032, growing at a CAGR of 26.23% over the forecast period of 2025-2032.
The global AI in oncology market has seen rapid development driven by the rising incidence of cancer, growing demand for precision treatment, and advances in AI technologies. While more than 20 million new cases of cancer are diagnosed each year globally, with lung cancer still the leading cause of cancer death, diagnostic performance is crucial to healthcare systems. AI in oncology plays a central role in early detection, risk stratification, and personalized treatment, with programs achieving diagnostic accuracy of over 90% in image-based cancer detection.
The U.S. AI in oncology market is advancing due to soaring investments, supportive regulations, and tech companies partnering with cancer centers. More than 25% of healthcare venture funding currently goes to AI-powered cancer solutions, and R&D investment in oncology AI jumped by a factor of 5–10 over the last five years. Oncology companies, such as PathAI, Tempus, and Paige, are utilizing AI solutions that can be easily incorporated into hospital workflow, accelerating both the speed and accuracy of diagnosis and clinical results. Rising availability of big data and cloud computing also enables the global AI in oncology market size and advanced AI model training.
Moreover, an increase in approvals for AI diagnostic tools and clinical decision support systems by the US FDA, and recommendations from the transcription industry and AHRQ CDSiC, is promoting the AI in oncology market growth from a long-term standpoint. Real-time tumor profiling, prediction of therapy response, and drug design are some of the use cases where AI solutions are being leveraged, pointing towards a new paradigm in cancer care.
For instance, one breakthrough was reached with the release at the beginning of 2024 of a deep-learning model for early-stage breast-cancer detection in mammography scans, which achieved an accuracy of 94.5%, outperforming average radiologist performance and providing an AI in the oncology market trend.
In May 2025, DeepScribe partnered with Flatiron Health to deliver ambient AI solutions tailored for oncology documentation to over 4,200 providers in Flatiron’s network.
Drivers:
Rising Demand for Precision Oncology and AI-Driven Clinical Tools Propel the Market Expansion
Rising complexity in cancer, adoption of personalized approach, and increasing requirement for quick and accurate diagnosis are driving the global AI in oncology market. Cancer diagnosis is transformed with AI algorithms providing up to 95% accuracy in detecting malignancies in CT and PET scans, and decreasing interpretation time by more than 50%. Hospital EMRs now include AI-enabled clinical decision support tools, and use of such tools at comprehensive cancer centers has grown 42% in the past three years from 2021-2024. By combining multi-omics and real-world evidence with patient genomics into AI, oncologists can personalize treatment regimens and improve outcomes.
In April 2025, Tempus signed expanded strategic agreements with AstraZeneca and Pathos to develop the largest multimodal foundation model in oncology globally, aiming to accelerate AI-powered drug discovery and precision treatment.
Demand is boosted by higher R&D expenditure, and global AI on cancer-related clinical trials has grown 4.7x over the last six years. There is also regulatory backing, and more than 30 cancer-related AI devices were approved by the U.S. FDA to use AI between 2019 and 2024, and organizations, such as CDSiC and ASCO, have produced prescriptive guidelines to promote ethical use of AI. AI in oncology companies is also enjoying significant funding support. AI drug discovery platforms bagged over USD 2.3 billion in investment in 2023 alone. The accelerating importance of cutting down on doctor burnout and decision fatigue has led to greater reliance on AI for planning treatments and reporting on radiology, an evolution that has helped keep alive the expanding AI in oncology market.
Restraints:
Data Privacy, Infrastructure Gaps, and Clinical Validation Challenges Hamper the Market Growth
Data privacy is one major hurdle, and 85% of healthcare leaders identify HIPAA and GDPR compliance as barriers to implementing AI at scale. AI is dependent on large, high-quality labeled datasets, however, hidden, fragmented EHR systems and non-standardized cancer registries block effective data transfer. Tumor detection sensitivity decreased by 21% in underrepresented populations, a 2023 study found, as AI algorithms often learn from non-diverse data, underpinning diagnostic inaccuracies among ethnic groups. Furthermore, clinical validation is incomplete, and only 12% of the oncological AI tools in the clinical trials are at the Phase III stage. Differences in infrastructure are also a barrier due as over 50% of mid-tier hospitals in developed countries describe a lack of GPU servers and IT resources to deliver AI solutions in real time.
From a regulatory perspective, although the FDA has approved AI tools, evolving SaMD (Software as a Medical Device) guidelines introduce compliance ambiguity. Furthermore, physician skepticism remains 40% of oncologists polled had reservations about AI interpretability and patient confidence. The resulting combined constraints may slow down holistic adoption and the speed of uptake of AI in the oncology market despite strong promise and high need.
By Component Type
In 2024, hardware is the leading category under the AI in oncology market, which was valued at 40.2% AI in oncology market share of revenue. This leadership is driven by the growing need for high-performance computing infrastructure, including GPUs, AI chips, and edge devices that can immediately process complex oncology datasets in real-time. Significant investment in AI-ready imaging equipment and data storage systems by hospitals and research centres was driving hardware adoption.
On the other hand, software solutions is expected to be the fastest-growing segment in the market, as AI-based solutions are increasingly being integrated with diagnostic platforms, workflow assistance, and decision support platforms. There is growing use of cloud-based AI software that analyzes multifaceted data (genomics and radiomics) to improve prediction and treatment planning for a broad range of oncology use cases.
By Cancer Type
In 2024, breast cancer was the largest segment of the AI in oncology market, accounting for an AI in oncology market share of 21.3%. The growth is attributed to the increasing number of mammography and digital breast tomosynthesis for early detection and classification, bolstered by AI algorithms. Additionally, breast cancer also benefits from high levels of screening programs and public awareness, resulting in a larger number of diagnoses.
For instance, in March 2025, Vanderbilt University Medical Center researchers announced their leadership in an AI-driven oncology workshop at AACR 2025, emphasizing advancements in deep learning for cancer research.
Meanwhile, the prostate cancer segment is expected to be the fastest growing, driven by the increase in AI-assisted MRI interpretation and image-guided biopsy optimization. AI is now facilitating accurate tumor mapping and risk grouping, enhancing clinical judgments and patient proactive outcomes in the management of prostate cancer.
By Application
In 2024, the most widespread application of AI in oncology was diagnostics, which occupied 37.3% of the total AI in oncology market. The prevalence of diagnostics is supported by the ever-increasing demand for accurate, point-of-care (POC), and high-throughput cancer detection devices. AI-augmented radiology and pathology systems also shorten diagnosis time and cut error rates, and can help clinicians find tumors at earlier stages.
The increase in use of AI tools to tailor drug dosing, predict toxicity, and assess responses to treatment, on the other hand, means that the chemotherapy category is projected to grow the fastest. This assists oncologists in personalizing the regimens and minimizing the side effects for enhanced patient care in chemotherapy-based treatment strategies.
By End Use
Hospitals dominated the AI in oncology market with the largest share of 49.3% during the forecast period due to the wide usage of AI-based imaging solutions, diagnostic tools, and treatment planning systems in hospitals. Hospitals act as the central access points for cancer diagnosis, treatment, and surgery, and are the single largest adopters of AI.
On the other hand, the highest growth rate is projected in the surgical centers and medical institutes with the rising demand for AI-powered robotic surgery systems, AI-enhanced intraoperative imaging systems, and AI-based precision oncology platforms. In addition, their ability to adopt emerging technologies and involvement in clinical research facilitate the wider adoption of AI in these specialized settings.
The North American region led the AI in oncology market in 2024, with high digitization in the healthcare market, the presence of leading market players specifically working in the field of AI-based oncology, and early adoption of AI-based technologies along with precision medicines in the region.
The U.S. AI in oncology market size was valued at USD 1.38 billion in 2024 and is expected to reach USD 8.26 billion by 2032, growing at a CAGR of 25.17% over the forecast period of 2025-2032. With the highest market share in the region, the U.S. is attributed to the presence of a large number of AI start-ups with well-established AI R&D infrastructure that emphasizes oncology (total R&D expenditure over USD 48 billion), and supportive government policies such as the FDA’s Software Precertification Program. In Canada, there is a growing uptake of AI driven by public-private partnerships and national AI strategies in cancer. The U.S. still leads usage as AI tools become more common in diagnosing and planning the treatment of oncology in leading cancer centers such as MD Anderson and Memorial Sloan Kettering. Cross-border foreign tech investments are gradually introducing AI platforms to Mexico, particularly in radiology and digital pathology.
The European AI in oncology market is the second-fastest-growing region in the world, driven by robust national healthcare systems, EU digital health laws, and cooperative R&D initiatives such as Horizon Europe. The European market is led by Germany, which is home to a well-established medical devices industry and a growing AI in radiotherapy planning integration in the country. Fastest-growing in the region, with NHS AI-backed breast cancer diagnostics studies and funding as part of the NHS AI Lab being key drivers. France and Italy are deploying personalized oncology platforms, and other countries, including Spain and Poland, are fast-tracking AI in hospital oncology workflows. Germany’s front is buttressed by corporations between healthcare workers and the artificial intelligence industry, which in turn upgrades clinical results and research.
Asia Pacific is the fastest-growing market in the AI in oncology market globally, primarily due to the increasing cancer prevalence, burgeoning need for improved analytical solutions in diagnostics, digital healthcare infrastructure, and government efforts. China is the regional leader and has the world’s most aggressive AI policies and investments in AI diagnostic platforms for hospitals, and its health AI industry passed USD 10 billion in 2024. India is fast catching up with its first AI Precision Oncology Center launched by Apollo Hospitals and government-supported AI missions. Robots and machine learning, being used in surgical oncology and diagnostics, Japan and South Korea are combining robotics and machine learning.
Australia and Singapore, for instance, are investing massively in joint research partnerships and integrating AI into cancer genomics. China is also buoyed up by a handful of mighty domestic tech players rolling out AI platforms with an oncology focus, such as Tencent and Alibaba.
Prominent AI in oncology companies operating in the market are Azra AI, IBM, Siemens Healthcare GmbH, Intel Corporation, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., ConcertAI, Median Technologies, PathAI, and MVision AI.
In April 2025, Azra AI announced an expansion of its end-to-end oncology platform, enhancing automation and care coordination features to further streamline cancer diagnosis and patient management.
In January 2025, Pathos AI emerged with USD 100 million in Series A funding to launch an AI platform focused on transforming oncology drug discovery and clinical trial optimization.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 4.22 Billion |
| Market Size by 2032 | USD 27.17 Billion |
| CAGR | CAGR of 26.23% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Component Type (Software Solutions, Hardware, and Services) • By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, and Others) • By Application (Diagnostics (Pathology, Cancer Radiology), Radiation therapy (Radiotherapy), Research & Development (Drug design, development process, etc.), Chemotherapy, and Immunotherapy) • By End Use (Hospitals, Surgical Centers & Medical Institutes, and Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Azra AI, IBM, Siemens Healthcare GmbH, Intel Corporation, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., ConcertAI, Median Technologies, PathAI, and MVision AI. |
Ans: The AI in Oncology market is anticipated to grow at a CAGR of 26.23% from 2025 to 2032.
Ans: The market is expected to reach USD 27.17 billion by 2032, increasing from USD 4.22 billion in 2024.
Ans: Rising complexity in cancer, adoption of personalized approach, and increasing requirement for quick and accurate diagnosis are driving the global AI in oncology market.
Ans: Data privacy is one major hurdle. 85% of healthcare leaders identify HIPAA and GDPR compliance as barriers to implementing AI at scale.
Ans: North America dominated the AI in Oncology market.
Table Of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Cancer Incidence and Prevalence, by Type (2024)
5.2 AI Adoption Rates in Oncology, by Region (2021–2024)
5.3 Oncology-focused AI Clinical Trials, by Region (2021–2024)
5.4 Oncology AI Software Usage Trends, by End User (Hospitals, Research Institutes, Pharma Companies), 2024
5.5 Investment and Funding in AI for Oncology, Global and Regional (2021–2024)
5.6 Healthcare IT Infrastructure Penetration, by Region, 2024
5.7 Cost Reduction and Efficiency Gains Attributed to AI Use in Oncology, 2024
5.8 Reimbursement and Regulatory Landscape for Oncology AI Solutions, by Region, 2024
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. AI in Oncology Market Segmentation By Component Type
7.1 Chapter Overview
7.2 Software Solutions
7.2.1 Software Solutions Market Trends Analysis (2021-2032)
7.2.2 Software Solutions Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Hardware
7.3.1 Hardware Market Trends Analysis (2021-2032)
7.3.2 Hardware Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Services
7.4.1 Services Market Trends Analysis (2021-2032)
7.4.2 Services Market Size Estimates and Forecasts to 2032 (USD Billion)
8. AI in Oncology Market Segmentation By Cancer Type
8.1 Chapter Overview
8.2 Breast Cancer
8.2.1 Breast Cancer Market Trends Analysis (2021-2032)
8.2.2 Breast Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Lung Cancer
8.3.1 Lung Cancer Market Trends Analysis (2021-2032)
8.3.2 Lung Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Prostate Cancer
8.4.1 Prostate Cancer Market Trends Analysis (2021-2032)
8.4.2 Prostate Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Colorectal Cancer
8.5.1 Colorectal Cancer Market Trends Analysis (2021-2032)
8.5.2 Colorectal Cancer Market Size Estimates and Forecasts To 2032 (USD Billion)
8.6 Brain Tumor
8.6.1 Brain Tumor Market Trends Analysis (2021-2032)
8.6.2 Brain Tumor Market Size Estimates and Forecasts To 2032 (USD Billion)
8.7 Others
8.7.1 Others Market Trends Analysis (2021-2032)
8.7.2 Others Market Size Estimates and Forecasts To 2032 (USD Billion)
9. AI in Oncology Market Segmentation By Application
9.1 Chapter Overview
9.2 Diagnostics (Pathology, Cancer Radiology)
9.2.1 Diagnostics (Pathology, Cancer Radiology) Market Trends Analysis (2021-2032)
9.2.2 Diagnostics (Pathology, Cancer Radiology) Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Radiation Therapy (Radiotherapy)
9.3.1 Radiation Therapy (Radiotherapy) Market Trends Analysis (2021-2032)
9.3.2 Radiation Therapy (Radiotherapy) Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Research & Development (Drug design, development process, etc.)
9.4.1 Research & Development (Drug design, development process, etc.) Market Trends Analysis (2021-2032)
9.4.2 Research & Development (Drug design, development process, etc.) Market Size Estimates and Forecasts to 2032 (USD Billion)
9.5 Chemotherapy
9.5.1 Chemotherapy Market Trends Analysis (2021-2032)
9.5.2 Chemotherapy Market Size Estimates and Forecasts to 2032 (USD Billion)
9.6 Immunotherapy
9.6.1 Immunotherapy Market Trends Analysis (2021-2032)
9.6.2 Immunotherapy Market Size Estimates and Forecasts to 2032 (USD Billion)
10. AI in Oncology Market Segmentation by End Use
10.1 Chapter Overview
10.2 Hospitals
10.2.1 Hospitals Market Trends Analysis (2021-2032)
10.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
10.3 Surgical Centers & Medical Institutes
10.3.1 Surgical Centers & Medical Institutes Market Trend Analysis (2021-2032)
10.3.2 Surgical Centers & Medical Institutes Market Size Estimates and Forecasts to 2032 (USD Billion)
10.4 Others
10.4.1 Others Market Trends Analysis (2021-2032)
10.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
11. Regional Analysis
11.1 Chapter Overview
11.2 North America
11.2.1 Trend Analysis
11.2.2 North America AI in Oncology Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.2.3 North America AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.2.4 North America AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.2.5 North America AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.2.6 North America AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.2.7 USA
11.2.7.1 USA AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.2.7.2 USA AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.2.7.3 USA AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.2.7.4 USA AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.2.8 Canada
11.2.8.1 Canada AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.2.8.2 Canada AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.2.8.3 Canada AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.2.8.4 Canada AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.2.9 Mexico
11.2.9.1 Mexico AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.2.9.2 Mexico AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.2.9.3 Mexico AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.2.9.4 Mexico AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.3 Europe
11.3.1 Trend Analysis
11.3.2 Europe AI in Oncology Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.3.3 Europe AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.3.4 Europe AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.3.5 Europe AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.6 Europe AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.3.7 Germany
11.3.7.1 Germany AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.3.7.2 Germany AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.3.7.3 Germany AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.7.4 Germany AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.3.8 France
11.3.8.1 France AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.3.8.2 France AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.3.8.3 France AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.8.4 France AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.3.9 UK
11.3.9.1 UK AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.3.9.2 UK AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.3.9.3 UK AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.9.4 UK AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.3.10 Italy
11.3.10.1 ItalyAI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.3.10.2 Italy AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.3.10.3 Italy AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.10.4 Italy AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.3.11 Spain
11.3.11.1 Spain AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.3.11.2 Spain AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.3.11.3 Spain AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.11.4 Spain AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.3.12 Poland
11.3.12.1 Poland AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.3.12.2 Poland AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.3.12.3 Poland AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.12.4 Poland AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.3.13 Turkey
11.3.13.1 Turkey AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.3.13.2 Turkey AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.3.13.3 Turkey AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.13.4 Turkey AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.3.14 Rest of Europe
11.3.14.1 Rest of Europe AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.3.14.2 Rest of Europe AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.3.14.3 Rest of Europe AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.14.4 Rest of Europe AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.4 Asia Pacific
11.4.1 Trend Analysis
11.4.2 Asia Pacific AI in Oncology Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.4.3 Asia Pacific AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.4.4 Asia Pacific AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.4.5 Asia Pacific AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.6 Asia Pacific AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.4.7 China
11.4.7.1 China AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.4.7.2 China AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.4.7.3 China AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.7.4 China AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.4.8 India
11.4.8.1 India AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.4.8.2 India AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.4.8.3 India AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.8.4 India AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.4.9 Japan
11.4.9.1 Japan AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.4.9.2 Japan AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.4.9.3 Japan AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.9.4 Japan AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.4.10 South Korea
11.4.10.1 South Korea AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.4.10.2 South Korea AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.4.10.3 South Korea AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.10.4 South Korea AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.4.11 Singapore
11.4.11.1 Singapore AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.4.11.2 Singapore AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.4.11.3 Singapore AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.11.4 Singapore AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.4.12 Australia
11.4.12.1 Australia AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.4.12.2 Australia AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.4.12.3 Australia AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.12.4 Australia AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.4.13 Rest of Asia Pacific
11.4.13.1 Rest of Asia Pacific AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.4.13.2 Rest of Asia Pacific AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.4.13.3 Rest of Asia Pacific AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.13.4 Rest of Asia Pacific AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.5 Middle East and Africa
11.5.1 Trend Analysis
11.5.2 Middle East and Africa AI in Oncology Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.5.3 Middle East and Africa AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.5.4 Middle East and Africa AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.5.5 Middle East and Africa AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.5.6 Middle East and Africa AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.5.7 UAE
11.5.7.1 UAE AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.5.7.2 UAE AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.5.7.3 UAE AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.5.7.4 UAE AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.5.8 Saudi Arabia
11.5.8.1 Saudi Arabia AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.5.8.2 Saudi Arabia AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.5.8.3 Saudi Arabia AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.5.8.4 Saudi Arabia AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.5.9 Qatar
11.5.9.1 Qatar AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.5.9.2 Qatar AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.5.9.3 Qatar AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.5.1.9.4 Qatar AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.5.10 South Africa
11.5.10.1 South Africa AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.5.10.2 South Africa AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.5.10.3 South Africa AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.5.10.4 South Africa AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.5.11 Rest of Middle East & Africa
11.5.11.1 Rest of Middle East & Africa AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.5.11.2 Rest of Middle East & Africa AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.5.11.3 Rest of Middle East & Africa AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.5.11.4 Rest of Middle East & Africa AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.6 Latin America
11.6.1 Trend Analysis
11.6.2 Latin America AI in Oncology Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.6.3 Latin America AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.6.4 Latin America AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.6.5 Latin America AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.6.6 Latin America AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.6.7 Brazil
11.6.7.1 Brazil AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.6.7.2 Brazil AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.6.7.3 Brazil AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.6.7.4 Brazil AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.6.8 Argentina
11.6.8.1 Argentina AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.6.8.2 Argentina AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.6.8.3 Argentina AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.6.8.4 Argentina AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
11.6.9 Rest of Latin America
11.6.9.1 Rest of Latin America AI in Oncology Market Estimates and Forecasts By Component Type (2021-2032) (USD Billion)
11.6.9.2 Rest of Latin America AI in Oncology Market Estimates and Forecasts By Cancer Type (2021-2032) (USD Billion)
11.6.9.3 Rest of Latin America AI in Oncology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.6.9.4 Rest of Latin America AI in Oncology Market Estimates and Forecasts by End Use (2021-2032) (USD Billion)
12. Company Profiles
12.1 Azra AI
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 IBM
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Siemens Healthcare GmbH
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 Intel Corporation
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 GE HealthCare
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 NVIDIA Corporation
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Digital Diagnostics Inc.
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 ConcertAI
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Triton
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Median Technologies
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
13. Use Cases and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Component Type
Software Solutions
Hardware
Services
By Cancer Type
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Brain Tumor
Others
By Application
Diagnostics (Pathology, Cancer Radiology)
Radiation therapy (Radiotherapy)
Research & Development (Drug design, development process, etc.)
Chemotherapy
Immunotherapy
By End Use
Hospitals
Surgical Centers & Medical Institutes
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players